Selection of new health technologies for assessment aimed at informing decision making: A survey among horizon scanning systems

被引:36
作者
Douw, K [1 ]
Vondeling, H [1 ]
机构
[1] Univ So Denmark, Dept Hlth Econ, DK-5000 Odense, Denmark
关键词
health technology assessment; horizon scanning systems; priority setting; new and emerging health technologies; decision making;
D O I
10.1017/S0266462306050999
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Uncertainty is pervasive in decision making on new health technologies; therefore, some countries have put systems in place to support decision makers with timely information. An important, but as yet undocumented, determinant of the potential value for decision making of these so-called horizon scanning systems (HSSs) is how the most significant health technologies are selected. Methods: All thirteen member organizations of EuroScan, a collaborative network for HSSs, were surveyed and interviewed on how they prioritize technologies for assessment. Results: The majority of HSSs directly serves a customer. Some customers actively request early assessments of new health technologies, thereby diminishing the need for priority setting for the HSSs. All systems express a concern to miss an important technology and/or to select an unimportant technology. Almost all HSSs use explicit selection criteria, but these criteria hardly ever are operationalized. The number of criteria used varies, but costs and health benefit of the technology are always taken into account. The process of reaching a final decision is implicit, undocumented in all but one system, and is based on agreement by consensus. Conclusions: The process of making the final decision on which technologies to assess can be improved by applying existing criteria more consistently and transparently. Current practice does not safeguard against missing an important technology. This finding is probably most important to act upon for systems with customers that do not actively request assessment of specific technologies.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 23 条
[1]   Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures [J].
Apolone, G ;
Joppi, R ;
Bertele, V ;
Garattini, S .
BRITISH JOURNAL OF CANCER, 2005, 93 (05) :504-509
[2]  
Banta H. David, 1994, World Health Statistics Quarterly, V47, P140
[3]  
Banta HD, 1998, INT J TECHNOL ASSESS, V14, P607
[4]  
BROWER V, 2002, EMBO REPORTS, V3
[5]   Health technology assessment and priority setting for health policy in Sweden [J].
Carlsson, P .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2004, 20 (01) :44-54
[6]   The future should not take us by surprise: Preparation of an early warning system in Denmark [J].
Douw, K ;
Vondeling, H ;
Sorensen, J ;
Jorgensen, T ;
Sigmund, H .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2004, 20 (03) :342-350
[7]  
DOWIE J, 2003, HLTH CARE PRIORITY S
[8]   Time-trends in health technology assessments: An analysis of developments in composition of international health technology assessments from 1989 to 2002 [J].
Draborg, E ;
Gyrd-Hansen, D .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2005, 21 (04) :492-498
[9]  
*EMEA, 2005, EUR MED AG PROP NEW
[10]  
*EUR INF NETW NEW, 2005, EUROSCAN STAT REP